Rnapc2

Unassigned

New Medicines

Ebola virus infection; treatment of viral haemorrhagic fever post-exposure to Ebola virus

Information

New molecular entity
Not Known
ARCA

Development and Regulatory status

None
None
None
01. Dec 14: FDA grants orphan drug designation to rNAPc2 as a potential treatment of viral haemorrhagic fever post-exposure to Ebola virus. It was originally developed as a cardiovascular therapy [1].
02. Dec 14: ARCA is currently exploring options for development of rNAPc2 including seeking development partners, out-licensing the compound and applying for grant or government funding. ARCA is not actively developing rNAPc2 for any indications and has no plans to begin such development without securing a partnership, an out-licensing agreement or receiving grant or government funding [1].

Category

A recombinant protein that interferes with the tissue factor/factor VIIa/factor Xa protease complex
Ebola virus is highly infectious and leads to a potentially fatal disease with fever, malaise, vomiting, mucosal and gastrointestinal bleeding, oedema, and hypotension. Mortality is 50-90% [2].
Ebola virus infection; treatment of viral haemorrhagic fever post-exposure to Ebola virus
Intravenous

Trial or other data

Previous research studies have shown that abnormal activation of tissue factor (TF) is a common element of the host response to infection from Ebola, Marburg and other HFVs. This activation of TF results in a systemic consumption coagulopathy and related inflammation, which is believed to be partially responsible for the high morbidity and mortality caused by these infections. rNAPc2 was identified as a potential therapeutic for HFV infection because of its unique mechanism of action in inhibiting TF [1].